US EditionEli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
UNITED STATES, AUG 7 – Orforglipron led to 12% average weight loss in an 18-month trial of over 3,000 adults with obesity, with 60% losing at least 10%, company data show.
- On August 7, 2025, Eli Lilly reported successful primary outcomes from its global Phase 3 ATTAIN-1 study evaluating orforglipron, an oral medication for obesity.
- The 72-week trial involved 3,127 adults with obesity or overweight and weight-related conditions but no diabetes, aiming to surpass placebo in body weight reduction.
- Participants on the highest 36 mg dose lost an average of 12.4% body weight , and 59.6% lost at least 10%, with side effects similar to injectable GLP-1 drugs.
- Eli Lilly aims to file for regulatory approval of orforglipron by the end of the year and is investing over $600 million in production capacity to support anticipated demand for its worldwide introduction in response to critical health challenges.
- The results position orforglipron as a convenient once-daily oral alternative for obesity treatment, with detailed data expected at a September conference and possible market entry next year.
Insights by Ground AI
Does this summary seem wrong?
41 Articles
41 Articles
Evening StandardReposted by 
The Independent
The IndependentHigh demand expected for new daily weight loss pill
The tablet could be a cheaper and more convenient alternative to injections.
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources41
Leaning Left6Leaning Right2Center17Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 24%
C 68%
Factuality
To view factuality data please Upgrade to Premium
